ライフサイエンスコーパス: guanosine monophosphate

1 a bacterial riboswitch that binds cyclic-di-guanosine monophosphate.

2 rease intracellular concentrations of cyclic guanosine monophosphate.

3 stiff because of low nitric oxide and cyclic guanosine monophosphate.

4 he Watson-Crick complementary nucleotide, 5'-guanosine monophosphate (5'-GMP), was seen in the case o

5 methyl ester (L-NAME), 8-bromo-cyclic 3',5'-guanosine monophosphate (8-bromo-cGMP), and nitroglyceri

6 e monophosphate [8br-cAMP] and 8bromo cyclic guanosine monophosphate [8br-cGMP]) in rat liver preserv

7 omo-cyclic AMP (8BrcAMP), and 8-bromo-cyclic guanosine monophosphate (8BrcGMP) also inhibited the glu

8 of sGCalpha1 is independent of NO and cyclic guanosine monophosphate, a major mediator of the sGC enz

9 Urinary excretion of cyclic guanosine monophosphate, a marker for renal NO productio

10 Tissue 3',5'-cyclic guanosine monophosphate, a potent vasodilator, was great

11 al and bradykinin-stimulated cellular cyclic guanosine monophosphate accumulation and L-citrulline co

12 nce or absence of 7-nitroindazole and cyclic guanosine monophosphate accumulation was determined.

13 mined in vitro in cardiac fibroblasts cyclic guanosine monophosphate-activating and antiproliferative

14 2'3'-cyclic guanosine monophosphate-adenosine monophosphate (2'3'-cG

15 the synthesis of a second messenger, cyclic guanosine monophosphate-adenosine monophosphate (2'3'-cG

16 Here we show that cytoplasmic sensor cyclic guanosine monophosphate-adenosine monophosphate (AMP) sy

17 led that SR-717 functions as a direct cyclic guanosine monophosphate-adenosine monophosphate (cGAMP)

18 The DNA sensor cyclic guanosine monophosphate-adenosine monophosphate (cGAMP)

19 tin without linker histone stimulates cyclic guanosine monophosphate-adenosine monophosphate (cGAMP)

20 e show that M. tuberculosis activated cyclic guanosine monophosphate-adenosine monophosphate (cGAMP)

21 we show that HIV infection activates cyclic guanosine monophosphate-adenosine monophosphate (cGAMP)

22 proaches led to the identification of cyclic guanosine monophosphate-adenosine monophosphate (cGAMP)

23 mimetic liposomes encapsulating 2',3'-cyclic guanosine monophosphate-adenosine monophosphate (cGAMP),

24 or of interferon genes (STING), 2'3'- cyclic guanosine monophosphate-adenosine monophosphate (cGAMP),

25 With the STING ligand cyclic guanosine monophosphate-adenosine monophosphate (cGAMP),

26 endogenous CDN ligand for STING, 2'3' cyclic guanosine monophosphate-adenosine monophosphate (cGAMP).

27 malian cytosolic extracts synthesized cyclic guanosine monophosphate-adenosine monophosphate (cyclic

28 interferons through the production of cyclic guanosine monophosphate-adenosine monophosphate (cyclic

29 ed liposome loaded with STING agonist cyclic guanosine monophosphate-adenosine monophosphate (NP-cGAM

30 ed an altered distribution of nuclear cyclic guanosine monophosphate-adenosine monophosphate synthase

31 The cyclic guanosine monophosphate-adenosine monophosphate synthase

32 riggered activation of the DNA sensor cyclic guanosine monophosphate-adenosine monophosphate synthase

33 Activation of the cyclic guanosine monophosphate-adenosine monophosphate synthase

34 a pathway dependent on the DNA sensor cyclic guanosine monophosphate-adenosine monophosphate synthase

35 V infection and mice lacking STING or cyclic guanosine monophosphate-adenosine monophosphate synthase

36 Cyclic guanosine monophosphate-adenosine monophosphate synthase

37 Guanosine monophosphate, among the nucleotides, has the

38 s, and these effects were mimicked by cyclic guanosine monophosphate analogs.

39 owing mRNA degradation, releasing N-7 methyl guanosine monophosphate and 5'-diphosphate terminated ca

40 cal pathway, such as the nitric oxide-cyclic guanosine monophosphate and endothelin pathways (eg, amb

41 In addition, CD-NP in vitro activates cyclic guanosine monophosphate and inhibits cardiac fibroblast

42 of cyclic adenosine monophosphate and cyclic guanosine monophosphate and is highly expressed in mediu

43 synthase (NOS) activity and decreased cyclic guanosine monophosphate and nitrite production.

44 admixture was calculated, and plasma cyclic guanosine monophosphate and sildenafil concentrations we

45 iated with elevation of intraplatelet cyclic guanosine monophosphate and was reversed by the nitric o

46 xide-dependent signaling (via sGC and cyclic guanosine monophosphate) and nitric oxide-independent si

47 of cyclic adenosine monophosphate and cyclic guanosine monophosphate, and, consequently, exhibit a ce

48 n vascular endothelial growth factor, cyclic guanosine monophosphate, angiogenesis, endogenous cell p

49 i indicates that NO signaling through cyclic guanosine monophosphate arose before the origin of multi

50 ieved using a reversible biogel formed by 5'-guanosine monophosphate as the run buffer in capillary e

51 f drugs that enhance the nitric oxide-cyclic guanosine monophosphate biological pathway (sildenafil,

52 e significantly increases cortical levels of guanosine monophosphate both in ischemic and nonischemic

53 second messenger bis-(3'-5')-cyclic-dimeric-guanosine monophosphate (c-di-GMP) acts as an innate imm

54 ane protein whose bis-(3',5')-cyclic dimeric guanosine monophosphate (c-di-GMP) binding activity post

55 he bacterial second messenger cyclic dimeric guanosine monophosphate (c-di-GMP) by posttranscriptiona

56 eased intracellular levels of cyclic dimeric guanosine monophosphate (c-di-GMP) compared to that of a

57 ignaling molecule bis-(3'-5')-cyclic dimeric guanosine monophosphate (c-di-GMP) controls important bi

58 second messenger bis-(3'-5')-cyclic dimeric guanosine monophosphate (c-di-GMP) controls secretion, c

59 The second messenger bis-3,5-cyclic di-guanosine monophosphate (c-di-GMP) determines when Strep

60 that catalyze formation of cyclic di-(3',5')-guanosine monophosphate (c-di-GMP) from GTP.

61 Bis-(3',5')-cyclic-dimeric-guanosine monophosphate (c-di-GMP) has been shown to be

62 a higher level of bis(3'-5')-cyclic dimeric guanosine monophosphate (c-di-GMP) in cells respiring on

63 Cyclic dimeric guanosine monophosphate (c-di-GMP) is a common, bacteria

64 Bis-(3'-5')-cyclic dimeric guanosine monophosphate (c-di-GMP) is a dynamic intracel

65 e bacterial second messenger cyclic di-3',5'-guanosine monophosphate (c-di-GMP) is a key regulator of

66 Cyclic di-(3':5')-guanosine monophosphate (c-di-GMP) is a major prokaryote

67 The cyclic dinucleotide cyclic-di-guanosine monophosphate (c-di-GMP) is a recently appreci

68 Cyclic dimeric guanosine monophosphate (c-di-GMP) is a ubiquitous signa

69 Cyclic di-guanosine monophosphate (c-di-GMP) is central to this pr

70 ly controls the intracellular cyclic dimeric guanosine monophosphate (c-di-GMP) level through a recep

71 Bis-(3'-5')-cyclic dimeric guanosine monophosphate (c-di-GMP) modulates the transit

72 second messenger bis-(3'-5')-cyclic dimeric guanosine monophosphate (c-di-GMP) plays a vital role in

73 The bis-(3'-5')-cyclic dimeric guanosine monophosphate (c-di-GMP) signaling pathway reg

74 activity towards bis-(3'-5')-cyclic dimeric guanosine monophosphate (c-di-GMP), but does not show di

75 erial secondary messenger, cyclic di-(3',5')-guanosine monophosphate (c-di-GMP), represents a balance

76 f the prokaryotic second messenger cyclic di-guanosine monophosphate (c-di-GMP), yet the signaling me

77 second messenger--bis-(3'-5')-cyclic dimeric guanosine monophosphate (c-di-GMP)--that perceives and t

78 osphodiesterase whose substrate is cyclic di-guanosine monophosphate (c-di-GMP)-a bacterial second me

79 second messenger bis-(3'-5')-cyclic dimeric guanosine monophosphate (c-di-GMP).

80 llular quadruplexes formed by cyclic dimeric guanosine monophosphate (c-di-GMP).

81 concentrations of cyclic 3',5'-adenosine and guanosine monophosphates (cAMP and cGMP, respectively) b

82 ation in vitro by preventing platelet cyclic guanosine monophosphate catabolism.

83 potensive mediators, nitric oxide and cyclic guanosine monophosphate, cause these phenotypes.

84 bacterial second messenger (3'-5')-cyclic-di-guanosine-monophosphate (CDG) is a promising mucosal adj

85 In vitro 3',5'-cyclic guanosine monophosphate (cGMP) activation in response to

86 Sildenafil and an analog of cyclic guanosine monophosphate (cGMP) also induced capillary-li

87 aBalpha accumulation; and b) a stable cyclic guanosine monophosphate (cGMP) analog (8-bromo-cGMP) to

88 3B (PDE3B), and a membrane-permeable cyclic guanosine monophosphate (cGMP) analog on KATP channel ac

89 onary circulation, the roles of cyclic 3'-5'-guanosine monophosphate (cGMP) and cGMP-phosphodiesteras

90 phosphodiesterase (PDE V) metabolizes cyclic guanosine monophosphate (cGMP) and is abundant in the ki

91 In healthy control subjects, urinary cyclic guanosine monophosphate (cGMP) and natriuresis increased

92 ) and significantly smaller levels of cyclic guanosine monophosphate (cGMP) and peroxisome proliferat

93 5 (PDE5) catalytic-site affinity for cyclic guanosine monophosphate (cGMP) and potency of inhibitors

94 se type 5 (PDE5) acts specifically on cyclic guanosine monophosphate (cGMP) and terminates cGMP-media

95 s study we tested the hypothesis that cyclic guanosine monophosphate (cGMP) and the dependent protein

96 c guanosine monophosphate (RpcGMP), a cyclic guanosine monophosphate (cGMP) antagonist, attenuated th

97 G protein-coupled receptors and cyclic guanosine monophosphate (cGMP) are implicated in the res

98 ic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP) are now recognized as imp

99 d evidence that nitric oxide (NO) and cyclic guanosine monophosphate (cGMP) are signaling intermediat

100 tion by using immunocytochemistry for cyclic guanosine monophosphate (cGMP) as an indicator.

101 ic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP) as well as calcium and pH

102 Agents that raise cyclic guanosine monophosphate (cGMP) by activating protein kin

103 Production of cyclic guanosine monophosphate (cGMP) by guanylate cyclase is o

104 ry vasodilation through activation of cyclic guanosine monophosphate (cGMP) by way of particulate gua

105 nce may, in part, relate to increased cyclic guanosine monophosphate (cGMP) catabolism by PDE5.

106 NO production, as estimated by aortic cyclic guanosine monophosphate (cGMP) concentration and endothe

107 m in dogs that results in lower basal cyclic guanosine monophosphate (cGMP) concentrations than in wi

108 and serum nitrite/ nitrate and atrial cyclic guanosine monophosphate (cGMP) concentrations were assay

109 Cyclic guanosine monophosphate (cGMP) content in the chamber ti

110 ic oxide synthase (NOS) activity, and cyclic guanosine monophosphate (cGMP) content were also assesse

111 Moreover, relaxation was cyclic guanosine monophosphate (cGMP) dependent and was inhibit

112 pothesized that nitric oxide promotes cyclic guanosine monophosphate (cGMP) formation, which, in turn

113 stimulates production and release of cyclic guanosine monophosphate (cGMP) from intestinal epithelia

114 The conclusion that cyclic 3'-5 guanosine monophosphate (cGMP) functions in a 'permissiv

115 ciated with a significant decrease in cyclic guanosine monophosphate (cGMP) generation after S-nitros

116 duction of the second messenger 3',5'-cyclic guanosine monophosphate (cGMP) have been shown to protec

117 by increases in intracellular cyclic 3', 5'-guanosine monophosphate (cGMP) in a small network of 50

118 trength and fluorescence response for cyclic guanosine monophosphate (cGMP) in an aqueous solution.

119 tion of NO, as estimated by measuring cyclic guanosine monophosphate (cGMP) in aortic tissue in two m

120 e (BNP) on cellular proliferation and cyclic guanosine monophosphate (cGMP) in human aortic vascular

121 9-I dose-dependently increased plasma cyclic guanosine monophosphate (cGMP) in normal sheep (p < 0.05

122 2A)) receptors increase production of cyclic guanosine monophosphate (cGMP) in slices of rat frontal

123 lices obtained from endotoxemic mice, cyclic guanosine monophosphate (cGMP) increased significantly a

124 trite and nitrate accumulation and by cyclic guanosine monophosphate (cGMP) increases in rat reporter

125 3',5'-cyclic guanosine monophosphate (cGMP) is a common second messen

126 Cyclic guanosine monophosphate (cGMP) is a key secondary messen

127 Cyclic guanosine monophosphate (cGMP) is a second messenger mol

128 Cyclic guanosine monophosphate (cGMP) is an important intracell

129 3',5'-Cyclic guanosine monophosphate (cGMP) is an important second me

130 The intracellular nucleotide cyclic guanosine monophosphate (cGMP) is found in many human or

131 Phosphodiesterase 5 (PDE5) hydrolyzes cyclic guanosine monophosphate (cGMP) leading to increased leve

132 and 28 days (n = 3) and evaluated for cyclic guanosine monophosphate (cGMP) levels (7 days), number o

133 th a short half-life, increases brain cyclic guanosine monophosphate (cGMP) levels and improves neuro

134 nger RNA (mRNA), protein, nitrite and cyclic guanosine monophosphate (cGMP) levels in Kupffer cells.

135 Cyclic 3',5'-guanosine monophosphate (cGMP) levels in the brainstem w

136 minute reperfusion cycles, myocardial cyclic guanosine monophosphate (cGMP) levels increased signific

137 Vascular cyclic guanosine monophosphate (cGMP) levels were elevated afte

138 ith and without SNP did not affect EC cyclic guanosine monophosphate (cGMP) levels, and the cGMP anal

139 osphorylation and activity as well as cyclic guanosine monophosphate (cGMP) levels, with all of these

140 guanylyl cyclase and, thus, enhances cyclic guanosine monophosphate (cGMP) levels.

141 Elevated intracellular levels of cyclic guanosine monophosphate (cGMP) may induce apoptosis, and

142 attributable to hyporesponsiveness of cyclic guanosine monophosphate (cGMP) mediated vasorelaxation e

143 In the vertebrate retina, cyclic guanosine monophosphate (cGMP) mediates photoreceptor si

144 ic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP) often mediate antagonisti

145 producing the intracellular messenger cyclic guanosine monophosphate (cGMP) on activation with nitric

146 es the kinase independently of the NO-cyclic guanosine monophosphate (cGMP) pathway and is coupled to

147 , the diatomic gas is critical to the cyclic guanosine monophosphate (cGMP) pathway as it functions a

148 ion of the atrial natriuretic peptide-cyclic guanosine monophosphate (cGMP) pathway in cardiac electr

149 A key component of the nitric oxide-cyclic guanosine monophosphate (cGMP) pathway in smooth muscle

150 ates a soluble guanylyl cyclase (sGC)-cyclic guanosine monophosphate (cGMP) pathway in the behavioral

151 tive (soluble) guanylyl cyclase (sGC)-cyclic guanosine monophosphate (cGMP) pathway regulates diverse

152 or tone and platelet activity via the cyclic guanosine monophosphate (cGMP) pathway, but whether coro

153 n of intracellular Ca2+ ([Ca2+]i) and cyclic guanosine monophosphate (cGMP) production (index of nitr

154 tudy was to determine whether hepatic cyclic guanosine monophosphate (cGMP) reduces NHGU.

155 NP (natriuretic peptide) receptor and cyclic guanosine monophosphate (cGMP) signaling has emerged as

156 provide evidence for a novel role of cyclic guanosine monophosphate (cGMP) signaling in the regulati

157 ne monophosphate (cAMP) and augmented cyclic guanosine monophosphate (cGMP) signaling is characterist

158 are key mediators of the nitric oxide/cyclic guanosine monophosphate (cGMP) signaling pathway that re

159 The cyclic guanosine monophosphate (cGMP) specific phosphodiesteras

160 Cyclic guanosine monophosphate (cGMP) stimulated human phosphod

161 urement of [Ca (2+)] i in response to cyclic guanosine monophosphate (cGMP) stimulation.

162 t on and independent of modulation of cyclic guanosine monophosphate (cGMP) subsequent to activation

163 A class of agonists can activate cyclic guanosine monophosphate (cGMP) synthesis by forms of sol

164 Assays of cyclic guanosine monophosphate (cGMP) synthesis from guanosine

165 as increased 11-fold and the K(i) for cyclic guanosine monophosphate (cGMP) was 27-fold higher than P

166 Cyclic guanosine monophosphate (cGMP) was measured by enzyme im

167 tigated whether nitric oxide (NO) and cyclic guanosine monophosphate (cGMP) were involved in memory c

168 xide (NO), catalyzes the formation of cyclic guanosine monophosphate (cGMP), an intracellular second

169 xpression and levels of nitric oxide, cyclic guanosine monophosphate (cGMP), and nitrotyrosine.

170 l methods to study the effects of NO, cyclic guanosine monophosphate (cGMP), and peroxynitrite on the

171 nctions through its second messenger, cyclic guanosine monophosphate (cGMP), and protein kinase G (PK

172 soluble guanosine cyclase to produce cyclic guanosine monophosphate (cGMP), and we observed that EPO

173 itric oxide pathway effector molecule cyclic guanosine monophosphate (cGMP), has been implicated in t

174 Cyclic guanosine monophosphate (cGMP), however, has been given

175 ic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP), is preferentially expres

176 The second messenger, cyclic guanosine monophosphate (cGMP), mediates the actions of

177 ated events, such as the induction of cyclic guanosine monophosphate (cGMP), NADPH diaphorase activit

178 diameter, and its upstream control by cyclic guanosine monophosphate (cGMP), nitrosative/oxidative st

179 hibitors and activators of sGC, 3',5'-cyclic guanosine monophosphate (cGMP), protein kinase G (PKG),

180 duces plexus neurons to produce cyclic 3',5' guanosine monophosphate (cGMP), suggesting the presence

181 nosine monophosphate (cAMP) and 3',5'-cyclic guanosine monophosphate (cGMP), which are second messeng

182 in follicular somatic cells, produces cyclic guanosine monophosphate (cGMP), which maintains meiotic

183 t, VWF did not promote an increase in cyclic guanosine monophosphate (cGMP), while agents that elevat

184 ownstream target of sildenafil in the cyclic guanosine monophosphate (cGMP)-activated protein kinase

185 el from Caenorhabditis elegans in the cyclic guanosine monophosphate (cGMP)-bound open state.

186 ds on NOS2 activity and the canonical cyclic guanosine monophosphate (cGMP)-cGMP-dependent protein ki

187 The gene Prkg2, encoding cyclic guanosine monophosphate (cGMP)-dependent protein kinase

188 Cyclic guanosine monophosphate (cGMP)-dependent protein kinase

189 nts are phosphorylated transiently by cyclic guanosine monophosphate (cGMP)-dependent protein kinase

190 is the foraging gene, which encodes a cyclic guanosine monophosphate (cGMP)-dependent protein kinase

191 signalling paradigm, we show that the cyclic guanosine monophosphate (cGMP)-dependent protein kinase,

192 reas the response to ascr#3 relies on cyclic guanosine monophosphate (cGMP)-gated channels and activi

193 tions in genes encoding subunits of a cyclic guanosine monophosphate (cGMP)-gated ion channel (tax-4

194 ndothelium-dependent and -independent cyclic guanosine monophosphate (cGMP)-mediated vasodilation in

195 a depolarizing conductance carried by cyclic guanosine monophosphate (cGMP)-sensitive cyclic nucleoti

196 ukocyte Mac-1-integrin activation and cyclic guanosine monophosphate (cGMP)-signaling, leading to red

197 uscle to the relaxant effects of 8-Br-cyclic guanosine monophosphate (cGMP).

198 d in markedly increased production of cyclic guanosine monophosphate (cGMP).

199 converts guanosine-5'-triphosphate to cyclic guanosine monophosphate (cGMP).

200 asing intracellular concentrations of cyclic guanosine monophosphate (cGMP).

201 label positively with an antibody to cyclic guanosine monophosphate (cGMP).

202 at recognize elevated levels of cyclic 3;,5;-guanosine monophosphate (cGMP).

203 ric oxide (NO) and increase levels of cyclic guanosine monophosphate (cGMP).

204 creasing pulmonary vascular levels of cyclic guanosine monophosphate (cGMP).

205 lyl-cyclase, GCY-8, which synthesizes cyclic guanosine monophosphate (cGMP).

206 ic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP).

207 on of calcium influx into the cell by cyclic guanosine monophosphate (cGMP).

208 ferative effect is mediated via an NO/cyclic guanosine monophosphate (cGMP)/cGMP-dependent protein ki

209 The elevated cyclic guanosine monophosphate (cGMP)/cGMP-dependent protein ki

210 r PDE activity in platelets is PDE3A (cyclic guanosine monophosphate [cGMP]-inhibited PDE).

211 ble guanylyl cyclase (which generates cyclic guanosine monophosphate, cGMP) was the first identified

212 By using immunohistochemistry against cyclic guanosine monophosphate, cochlear sGC activity was local

213 97%, -0.61%; P = 0.04) and attenuated cyclic guanosine monophosphate concentrations.

214 inorganic nitrate-nitrite, myocardial cyclic guanosine monophosphate content by neprilysin or phospho

215 reduces nitric oxide bioavailability, cyclic guanosine monophosphate content, and protein kinase G (P

216 genes putatively involved in cyclic-dimeric guanosine monophosphate (cyclic-di-GMP) metabolism.

217 -cGMP) and N(2),2'-o-dibutyryl 3', 5'-cyclic guanosine monophosphate (dB-cGMP), and of the selective

218 endogenous peptide ligands initiates cyclic guanosine monophosphate-dependent (cGMP) salt and water

219 cycle progression, which include both cyclic guanosine monophosphate-dependent and -independent pathw

220 teins involved in the mating process, cyclic guanosine monophosphate-dependent kinase, and the cation

221 vessels from endotoxemic animals in a cyclic guanosine monophosphate-dependent manner, suggesting tha

222 The arrest was downstream of cyclic guanosine monophosphate-dependent protein kinase (PfPKG)

223 4-kinase type III beta (PI4Kbeta) and cyclic guanosine monophosphate-dependent protein kinase (PKG) w

224 either guanylyl cyclase A receptor or cyclic guanosine monophosphate-dependent protein kinase in cult

225 lar signal-related kinase pathway via cyclic guanosine monophosphate-dependent protein kinase signali

226 Cyclic di-guanosine monophosphate (di-GMP) is a circular RNA dinuc

227 sis associated with increased urinary cyclic guanosine monophosphate excretion (UcGMPV), glomerular f

228 the formation of 3', 5'-cyclic adenosine or guanosine monophosphate from the corresponding nucleosid

229 ose media was paralleled by decreased cyclic guanosine monophosphate generation; however, there was n

230 nhibition of 3'-->5' exonuclease activity by guanosine monophosphate (GMP) abolished the ability of p

231 osphate (XMP), the committed step in de novo guanosine monophosphate (GMP) biosynthesis.

232 phate (PRPP) binding to the enzyme first and guanosine monophosphate (GMP) dissociating last.

233 uple biotin to a 'caged' photocleavable (PC) guanosine monophosphate (GMP) in high yield.

234 In dilute 5'-guanosine monophosphate (GMP) solutions, G-quartets form

235 genetic approach in zebrafish, we found that guanosine monophosphate (GMP) synthetase mutant larvae d

236 catalyze the breakdown of cAMP and/or cyclic guanosine monophosphate (GMP) to their inactive form.

237 We show that the coassembly of guanosine monophosphate (GMP) with an azobenzene-contain

238 riggers the innate immune response is cyclic guanosine monophosphate (GMP)-adenosine monophosphate (A

239 Cyclic guanosine monophosphate (GMP)-adenosine monophosphate (A

240 tructure of Acb4 in complex with 3'3'-cyclic guanosine monophosphate (GMP)-AMP (3'3'-cGAMP) reveals a

241 the recognition of cytosolic mtDNA by cyclic guanosine monophosphate (GMP)-AMP synthase (cGAS).

242 creased in parallel with a decline in cyclic guanosine monophosphate (GMP).

243 petitive substrate for ecto-5'-nucleotidase (guanosine monophosphate, GMP) did not affect basal VP re

244 Other strategies to increase tissue cyclic guanosine monophosphate have been attempted, such as PDE

245 Most cyclic guanosine monophosphate hydrolysis (about 80%) in cultur

246 Sildenafil is a potent inhibitor of cyclic guanosine monophosphate hydrolysis [corrected] in the co

247 Type 5 is the main factor regulating cyclic guanosine monophosphate hydrolysis and downstream signal

248 ogenous NO also was examined by using cyclic guanosine monophosphate immunocytochemistry.

249 de novo syntheses of inosine, adenosine and guanosine monophosphates (IMP, AMP and GMP) are importan

250 ficity cyclic adenosine monophosphate/cyclic guanosine monophosphate-inhibiting enzyme.

251 Cyclic guanosine monophosphate is mainly hydrolyzed by PDE (pho

252 , atrial natriuretic peptide, urinary cyclic guanosine monophosphate), Kansas City Cardiomyopathy Que

253 a greater elevation of intracellular cyclic guanosine monophosphate levels compared with nitric oxid

254 Reduced cyclic guanosine monophosphate levels contribute to HF progress

255 ricles from Cav-3 OE mice had greater cyclic guanosine monophosphate levels, less nuclear factor of a

256 Neither cyclic guanosine monophosphate nor guanylate cyclase were invol

257 Adenosine, uridine, and guanosine monophosphate nucleotides have approximately e

258 guanosine triphosphate to cGMP (cyclic 3',5'-guanosine monophosphate) on binding of ANP, BNP (atrial

259 thesis can be stimulated by the inclusion of guanosine monophosphate or specific oligoribonucleotides

260 NO-stimulated platelet generation of cyclic guanosine monophosphate (p < 0.02) but not with changes

261 the ability to activate plasma 3',5'-cyclic guanosine monophosphate (p < 0.05 vs. placebo).

262 zed ex vivo by augmentation of the NO-cyclic guanosine monophosphate pathway without normalization of

263 which they detect through a rhodopsin-cyclic guanosine monophosphate pathway.

264 Mechanisms of action of nitric oxide/cyclic guanosine monophosphate/PDE5 pathway in the treatment of

265 llele of the gamma subunit of retinal cyclic guanosine monophosphate phosphodiesterase (PDE gamma) su

266 oward the effector of transducin, the cyclic guanosine monophosphate phosphodiesterase.

267 site mutation in intron 2 of the rod cyclic guanosine monophosphate-phosphodiesterase (cGMP) beta-su

268 ceptor-specific expression of the rod cyclic guanosine monophosphate-phosphodiesterase beta-subunit (

269 racellular matrix remodeling via PDE5/cyclic guanosine monophosphate-PKG regulatory pathways.

270 phodiesterases (PDEs), which degrade cGMP to guanosine monophosphate, play key role in controlling th

271 -treated kidneys had higher levels of cyclic guanosine monophosphate, potentially explaining the perf

272 of Mg2+ concentration and the 2' OH group of guanosine monophosphate, prG, substrate on various steps

273 RO-25-6760, increased NPR-A-dependent cyclic guanosine monophosphate production and NPR-A gene expres

274 in reporter cells resulted in higher cyclic guanosine monophosphate production compared with the wil

275 lable BNP assays and cell activity by cyclic guanosine monophosphate production in vascular cells.

276 ic oxide synthase 1 blockade inhibits cyclic guanosine monophosphate production; 3) pharmacological b

277 x pathways that involve nitric oxide, cyclic guanosine monophosphate, protein kinase G, extracellular

278 nduce vasodilatation via nitric oxide-cyclic guanosine monophosphate-protein kinase G (i.e. NO/cGMP/P

279 Low myocardial cGMP-PKG (cyclic guanosine monophosphate-protein kinase G) activity has b

280 Plasma BNP and 3',5'-cyclic guanosine monophosphate rapidly increased and peaked at

281 and influencing the adenosine monophosphate/guanosine monophosphate ratio.

282 One of these encodes rat guanosine monophosphate reductase (GMP-r).

283 We further demonstrate that the gene for guanosine monophosphate reductase (GMPR) is a direct MIT

284 f At IMPDH conforms to the IMP dehydrogenase/guanosine monophosphate reductase motif and contains an

285 as the mRNA levels of uncoupling protein 1, guanosine monophosphate reductase, and peroxisome prolif

286 xide synthase inhibitor, and Rp-8 CPT-cyclic guanosine monophosphate (RpcGMP), a cyclic guanosine mon

287 -targeted regulation of cardiomyocyte cyclic guanosine monophosphate-selective phosphodiesterase type

288 sphodiesterase-5 inhibitors and other cyclic guanosine monophosphate signaling activators worked syne

289 d treatment with N-acetylcysteine and cyclic guanosine monophosphate signaling enhancers warrants fur

290 Abnormal cyclic guanosine monophosphate signaling may contribute to phys

291 neurons, which utilize diverse cyclic 3',5'-guanosine monophosphate signaling pathways and could ser

292 Sildenafil (SIL) inhibits cyclic guanosine monophosphate-specific PDE5A and can blunt the

293 bosyl pyrophosphate (PRPP) amidotransferase, guanosine monophosphate synthetase (GMPS) will not utili

294 Guanosine monophosphate synthetase is essential for de n

295 te cyclase and a higher production of cyclic guanosine monophosphate that together may help explain s

296 ssenger c-di-GMP (Bis-(3'-5')-cyclic dimeric guanosine monophosphate), to make a vital choice: whethe

297 anylate cyclase domains that mobilize cyclic guanosine monophosphate upon binding of peptide.

298 The levels of nitric oxide and cyclic guanosine monophosphate were also significantly reduced

299 , Na2 [(HGMP)2 Mo5 O15 ]7 H2 O (1; where GMP=guanosine monophosphate), which spontaneously assembles

300 ide-dependent excretion of sodium and cyclic guanosine monophosphate without affecting mean arterial